Companion-animal patients on multiple medications — the polypharmacy patient — are increasingly likely to also receive broad-spectrum CBD. This reference frames how CBD and cannabidiolic acid (CBDA) can interact with common veterinary co-medications, and how those interactions can be managed (and sometimes turned into a dose-sparing opportunity) rather than simply avoided. It covers dogs and cats.
Species considerations: dogs and cats
Both species share a similar interaction logic but differ markedly in hepatic clearance. The framework below is built on dog-specific CYP450 data. For feline patients, start at 0.5 mg/kg rather than 1–2 mg/kg: cats clear CBD more slowly than dogs. Begin low and titrate upward to response; all tier logic still applies.
Three types of interaction
Broad-spectrum CBD (CBD + CBDA + minor cannabinoids, <0.2% THC) can interact with a co-medication in three distinct ways:
| Type | What happens |
|---|---|
| Shared hepatic enzyme (CYP450) | CBDA inhibits CYP2B11 + CYP2D15; CBD inhibits CYP2B11. Neither inhibits canine CYP3A12. |
| Shared receptor | CBD acts at the same receptor as the co-medication (5-HT1A, GABA-A, mu/delta opioid). |
| Convergent effect | CBD and the co-medication reach the same clinical result (pain, inflammation, pruritus, anxiety) via different mechanisms. |
The interaction tiers at a glance
| Tier | Label | Synergy | What to monitor |
|---|---|---|---|
| Tier 1 | Independent pathways | Low | No specific monitoring up to 4 mg/kg CBD; baseline hepatic panel advised. |
| Tier 2 | Convergent pathways | Moderate | No specific monitoring up to 4 mg/kg; baseline hepatic panel advised. |
| Tier 3a | Shared receptor | High | Watch for potentiated drug (side)effects; baseline hepatic panel. |
| Tier 3b | Receptor + hepatic pathway | Maximum | Potentiated effects + hepatic enzymes (ALP, ALT). |
| Tier 3c | Narrow therapeutic index | Critical | Drug-specific monitoring (blood pressure, therapeutic levels); hepatic panel baseline + 2–4 weeks. |
Quick decision tree
In most cases a single question is enough. Most patients are Tier 1 or 2. The overlaps to watch for are: serotonergic receptor · opioid receptor · hepatic metabolism.
- No overlap at all? Tier 1 — combine freely, no timing restriction, no monitoring.
- Same clinical target, different mechanisms? Tier 2 — start 1 mg/kg, review at 2 weeks, titrate to result.
- Shared receptor only? Tier 3a — start 1 mg/kg; add monitoring for potentiated drug effects. Consider 2-hour dose spacing for peak coverage if the owner can comply; simultaneous dosing still works.
- Shared receptor + shared hepatic enzyme? Tier 3b — start 1 mg/kg; more cautious hepatic monitoring; consider 4-hour spacing.
- Narrow therapeutic index? Tier 3c — start 1 mg/kg; drug-specific monitoring; 4-hour spacing.
- Hepatic monitoring needed? For higher doses (5 mg/kg) or when combining with hepatotoxic co-medications. A baseline hepatic panel is always prudent.
Tier 1 — Independent
No shared enzymes, receptors or convergent effects. CBD's therapeutic domains do not overlap these drugs' targets — combine freely, any time.
| Medication | Mechanism |
|---|---|
| Antibiotics (amoxicillin, metronidazole) | Bacterial targets — no CBD overlap |
| Antifungals (ketoconazole, itraconazole) | Fungal targets |
| Antiparasitics (fenbendazole, ivermectin) | Parasitic targets |
| Insulin | Glucose regulation |
| Thyroid medication (levothyroxine) | Thyroid hormone replacement |
Protocol: start CBD 1–2 mg/kg/day alongside current medication; no dose change to anything. Timing irrelevant. CBD provides its own independent benefits (homeostatic, anti-inflammatory support); it is purely additive here — no co-medication reduction is expected or recommended.
Tier 2 — Convergent effects
CBD and the co-medication reach the same clinical result via completely different receptors and pathways. The effect is additive, not competitive. CBD reduces inflammation via PPARγ activation, NF-κB inhibition and adenosine signalling — distinct from the COX pathway of NSAIDs or the JAK pathway of oclacitinib.
| Medication | Converging on |
|---|---|
| NSAIDs (carprofen, meloxicam); COX-2 selective (firocoxib, robenacoxib, cimicoxib) | Inflammation / pain |
| Bedinvetmab (Librela), Frunevetmab (Solensia) — anti-NGF mAbs | Pain |
| Oclacitinib (Apoquel) — JAK inhibition | Pruritus / immune |
| Lokivetmab (Cytopoint) — anti-IL-31 mAb | Pruritus / immune |
| Corticosteroids (prednisolone, dexamethasone) | Immune modulation (CBD potentiates dexamethasone in canine PBMCs) |
| Gabapentin, pregabalin (α2δ calcium channel) | Pain / anxiety modulation |
| Levetiracetam (SV2A binding, minimal hepatic metabolism) | Seizure control |
Protocol & dose-sparing opportunity: start CBD 1–2 mg/kg. Reassess at 2 weeks. If clinical response holds or improves, reduce the co-medication by a maximum of 25%, hold CBD, and reassess in 2 weeks — changing one variable at a time. Goal: minimum effective drug dose, maximum cannabinoid support. If response drops, restore the co-medication to its previous effective dose (always safe and immediately reversible) before trying again.
Tier 3a — Shared receptor only
CBD occupies the same receptor as the co-medication but does not compete for the same hepatic enzyme. Consider 2-hour spacing to convert an unpredictable peak-to-peak interaction into controlled synergy.
| Medication | Shared receptor | Watch for |
|---|---|---|
| Phenobarbital | GABA-A (CBD is a positive allosteric modulator; Doran et al. 2021 found no significant PK interaction even at 10 mg/kg) | Excess sedation, ataxia, ALP elevation |
| Trazodone | 5-HT1A (trazodone is metabolised via CYP3A12, which CBD/CBDA do not inhibit — interaction is purely receptor-level) | Over-sedation, disorientation, hypotension |
Tier 3b — Shared receptor + hepatic enzyme
Two overlaps — the deepest synergy and the greatest dose-reduction potential. Consider 4-hour spacing and more cautious hepatic monitoring.
| Medication | Mechanism | Watch for |
|---|---|---|
| Amitriptyline | CBDA inhibits CYP2D15 (IC50 5.0 µM); 5-HT1A overlap. A human DDI study confirmed CBD raises amitriptyline AUC ~13%. | Sedation, tachycardia, dry mouth, urinary retention |
| Clomipramine (Clomicalm) | Same CYP2D15 route; serotonin/NA reuptake overlaps 5-HT1A agonism | Tremor, hyperthermia, diarrhoea, agitation |
| Fluoxetine | CBDA inhibits CYP2D15; fluoxetine also inhibits CYP2C19 (may raise CBD levels); 5-HT1A overlap | Diarrhoea, inappetence, lethargy, tremor |
| Sertraline | CBDA inhibits CYP2D15; 5-HT1A overlap | Diarrhoea, vomiting, fatigue, fever |
| Tramadol | CBD inhibits CYP2B11-mediated N-demethylation (IC50 4.6 µM); CBDA inhibits CYP2D15 O-demethylation (IC50 5.0 µM); CB1 and mu-opioid receptors are colocalised | Sedation, vomiting, tremor, dilated pupils (serotonergic signs) |
| Venlafaxine | CYP2D15 (canine CYP2D6 homologue); serotonin/NA receptor overlap | Serotonergic signs, elevated BP, GI upset |
Monitoring: baseline hepatic panel (ALP, ALT) + review at 2–4 weeks regardless of CBD dose; also watch sedation and serotonergic signs.
Tier 3c — Narrow therapeutic index
Potent combination — monitor to maximise. 4-hour spacing plus drug-specific monitoring.
| Medication | Why margin matters | Monitoring |
|---|---|---|
| Amlodipine | Both lower blood pressure (L-type Ca2+ channel vs ECS vasodilation) — small changes matter | Blood pressure (baseline, 1 wk, 2 wk) |
| Ciclosporin | Both suppress immunity (calcineurin vs ECS/CB2) — risk of over-immunosuppression | Therapeutic drug levels (baseline, 2 wk) |
Canine CYP specifics (Court et al. 2024)
Canine CYP2D15 and CYP3A12 are more resistant to CBD inhibition than their human orthologues CYP2D6 and CYP3A4.
| CYP enzyme | Inhibited by CBD? | Inhibited by CBDA? | IC50 | Key substrates |
|---|---|---|---|---|
| CYP2B11 | Yes | Yes | 4.6–8.1 µM | Tramadol (N-demethylation) |
| CYP2D15 | No | Yes | 5.0 µM | Fluoxetine, sertraline, tramadol (O-demethylation), tricyclics |
| CYP3A12 | No | No | >10 µM | Trazodone, ciclosporin, amlodipine — NOT inhibited |
Hepatic monitoring protocol
No liver injury has been demonstrated at standard therapeutic doses; ALP elevations are dose-dependent and reversible.
| CBD dose | Hepatic signal | Action |
|---|---|---|
| 1–4 mg/kg/day | Minimal/no ALP change | No hepatic monitoring needed for CBD alone; monitor if the co-medication already carries hepatic load |
| 5–10 mg/kg/day | Statistically significant ALP rise (enzyme induction; no liver injury shown at 36 weeks) | Baseline panel + periodic ALP (every 3–6 months) |
| ≥10 mg/kg/day | Significant ALP rise + GI effects | Baseline, 4-week, then 3-monthly; consider dose reduction |
Panel components: ALT, AST, albumin, ALP and GGT (GGT as a more specific marker of drug-induced hepatic injury in dogs). Add bilirubin when cholestasis or icterus is suspected. Note: isolated ALP elevation is non-specific — steroid hepatopathy is a common non-pathological cause in dogs. Consider a hepatoprotectant (e.g. SAMe, silymarin) when combining CBD with Tier 3b drugs.
Condition-specific considerations
After identifying the drug-interaction tier, consider the patient's underlying condition. All patients can benefit; the tier tells you how much attention to pay, not whether to use CBD.
- Chronic pain / osteoarthritis: the most-studied indication (RCTs show significant pain reduction at 2 mg/kg BID). Most co-drugs are Tier 1; tramadol is Tier 3a.
- Anxiety / behaviour: CBD is a 5-HT1A agonist. Trazodone is Tier 2 (2-h spacing); SSRIs/tricyclics are Tier 3b (4-h spacing).
- Cognitive dysfunction (CDS): neuroprotective/antioxidant/anti-neuroinflammatory; selegiline is likely Tier 2. Strong multimodal candidate for seniors.
- Dermatology / atopy: immune modulation via PPARγ/adenosine/NF-κB. Complementary to oclacitinib (Tier 2) and lokivetmab (Tier 1).
- Epilepsy: anticonvulsant efficacy shown in dogs. Phenobarbital is Tier 2 (GABA-A), levetiracetam Tier 1. Apply the 2-week stabilisation rule.
- Immune-mediated / GI disease: corticosteroids Tier 2, ciclosporin Tier 3b. Watch for over-immunosuppression.
- Geriatric: start 0.5–1 mg/kg, extend stabilisation to 3–4 weeks. Greatest polypharmacy-reduction benefit.
- Polypharmacy (3+ drugs): identify every drug's tier first, then apply the highest tier's protocol; stagger CBD dosing to maximise spacing from the most sensitive co-medication.
- Hepatic disease: start 0.5 mg/kg, mandatory hepatic monitoring. The paradox: CBD may help most here (by allowing NSAID/steroid reduction) yet needs the most careful introduction.
- Cardiac / hypotension: CBD has vasodilatory effects; with amlodipine apply Tier 3b (4-h spacing) and BP monitoring. Contraindicated in uncontrolled hypotension.
- Renal disease: CBD is cleared mainly hepatically; monitor renal values and co-medication accumulation. Emerging evidence suggests possible nephroprotective properties.
Key references
Court MH, Mealey KL, Burke NS, et al. Cannabidiol and cannabidiolic acid: preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P-450, UGT and P-glycoprotein. J Vet Pharmacol Ther. 2024. · Doran CE, McGrath S, Bartner LR, et al. Drug–drug interaction between cannabidiol and phenobarbital in healthy dogs. AJVR. 2021. · Verrico CD, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for canine osteoarthritis pain. Pain. 2020. · Vaughn DM, et al. 28-day safety and pharmacokinetics of repeated oral CBD in healthy dogs. AJVR. 2021. · Corsato Alvarenga I, et al. Tolerability of long-term CBD supplementation in healthy adult dogs. JVIM. 2023. · Gorbenko AA, et al. Low-dose cannabidiol increases plasma concentrations of amitriptyline: a clinical DDI study. Br J Clin Pharmacol. 2025. · Gilmartin CGS, et al. Interaction of cannabidiol with other antiseizure medications. Seizure. 2021. · Lima TM, et al. Use of cannabis in the treatment of animals: a systematic review of RCTs. Anim Health Res Rev. 2022.
This reference is for licensed veterinary professionals and is compiled from peer-reviewed research. It is not a substitute for individual clinical judgement, current product labelling, or local regulations on cannabinoid use in animals.